AR060334A1 - Derivados de benzimidazol - Google Patents

Derivados de benzimidazol

Info

Publication number
AR060334A1
AR060334A1 ARP070101297A ARP070101297A AR060334A1 AR 060334 A1 AR060334 A1 AR 060334A1 AR P070101297 A ARP070101297 A AR P070101297A AR P070101297 A ARP070101297 A AR P070101297A AR 060334 A1 AR060334 A1 AR 060334A1
Authority
AR
Argentina
Prior art keywords
carbon atoms
alkyl
mono
optionally substituted
halogen
Prior art date
Application number
ARP070101297A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR060334A1 publication Critical patent/AR060334A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticmente aceptable o éster de profármaco del mismo: en donde R es halogeno o alquilo de 1 a 6 átomos de carbono opcionalmente sustituido; X se selecciona del grupo que consiste de O, NH, CH2, CO, SO, SO2, o S; Y representa un grupo seleccionado de lo siguiente: alquilo de 1 a 6 átomos de carbono opcionalmente sustituido: -SR1, -S(O)R1, -S(O)2R1, -OR2, en donde R1 y R2 se seleccionan de alquilo de 1 a 6 átomos de carbono, alquenilo de 1 a 4 átomos de carbono o alquinilo de 1 a 4 átomos de carbono, opcionalmente sustituido; el sustituyente o sustituyentes opcionales en R, R1, R2 e Y se seleccionan independientemente del grupo que consiste de halogeno, hidroxi, alquilo de 1 a 6 átomos de carbono, mono- o di- alquilamino de 1 a 6 átomos de carbono, aminocarbonilo, sulfinilo, sulfonilo, sulfanilo, mono- o di-alquilaminocarbonilo de 1 a 6 átomos de carbono, amino, carboxi, alcoxi de 1 a 6 átomos de carbono, alqueniloxi de 2 a 6 átomos de carbono, alquiniloxi de 2 a 6 átomos de carbono, cicloalquilo de 3 a 12 átomos de carbono, heterocicloalquilo de 3 a 18 átomos de carbono, alquilcarbonilo de 1 a 6 átomos de carbono, alcoxicarbonilo de 1 a 6 átomos de carbono, nitrilo, arilo; todos estos excepto el halogeno, están independiente y opcionalmente sustituidos por uno o más sustituyentes seleccionados deI grupo que consiste de halogeno, hidroxi, alquilo de 1 a 6 átomos de carbono, mono- o di- alquilamiento de 1 a 6 átomos de carbono, aminocarbonilo, sulfinilo, sulfonilo, sulfanilo, mono- o dialquilaminocarbonilo de 1 a 6 átomos de carbono, amino, carboxi, alcoxi de 1 a 6 átomos de carbono, cicloalquilo de 3 a 12 átomos de carbono, heterocicloalquilo de 3 a 18 átomos de carbono, alquilcarbonilo de 1 a 6 átomos de carbono, alcoxicarbonilo de 1 a 6 átomos de carbono, nitrilo, arilo.
ARP070101297A 2006-03-30 2007-03-28 Derivados de benzimidazol AR060334A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0606426.5A GB0606426D0 (en) 2006-03-30 2006-03-30 Benzimidazole derivatives

Publications (1)

Publication Number Publication Date
AR060334A1 true AR060334A1 (es) 2008-06-11

Family

ID=36424926

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101297A AR060334A1 (es) 2006-03-30 2007-03-28 Derivados de benzimidazol

Country Status (24)

Country Link
US (1) US20100227889A1 (es)
EP (1) EP2004629A2 (es)
JP (1) JP2009531363A (es)
KR (1) KR20080110769A (es)
CN (1) CN101400669A (es)
AR (1) AR060334A1 (es)
AU (1) AU2007234021B2 (es)
BR (1) BRPI0710180A2 (es)
CA (1) CA2644380A1 (es)
CL (1) CL2007000850A1 (es)
CR (1) CR10199A (es)
EC (1) ECSP088781A (es)
GB (1) GB0606426D0 (es)
GT (1) GT200800200A (es)
IL (1) IL193475A0 (es)
MA (1) MA30341B1 (es)
MX (1) MX2008012403A (es)
NO (1) NO20084543L (es)
PE (1) PE20071149A1 (es)
RU (1) RU2008142831A (es)
TN (1) TNSN08369A1 (es)
TW (1) TW200806647A (es)
WO (1) WO2007112913A2 (es)
ZA (1) ZA200806833B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426391B2 (en) 2006-02-03 2013-04-23 Proventiv Therapeutics, Llc Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
SI2679228T1 (en) 2006-06-21 2018-06-29 Opko Ireland Global Holdings, Ltd. THERAPY WITH THE USE OF VITAMIN D ADDITIONAL FIBER AND HORMON RESISTANCE OF VITAMIN D
DK3342405T3 (da) 2007-04-25 2019-11-11 Opko Ireland Global Holdings Ltd Kontrolleret frigivelse af 25-hydroxyvitamin d
ES2403107T3 (es) 2007-04-25 2013-05-14 Cytochroma Inc. Método de tratamiento de insuficiencia y deficiencia de vitamina D
EP3636280A1 (en) 2010-03-29 2020-04-15 Opko Ireland Global Holdings, Ltd. Methods and compositions for reducing parathyroid levels
WO2012069402A1 (en) * 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
SG10201911274TA (en) 2014-08-07 2020-02-27 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
SG10201913863TA (en) 2016-03-28 2020-03-30 Opko Ireland Global Holdings Limited Methods of vitamin d treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000026430A (ja) * 1998-07-02 2000-01-25 Taisho Pharmaceut Co Ltd ２、５、６−置換ベンズイミダゾール化合物誘導体
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US7622592B2 (en) * 2002-11-01 2009-11-24 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
GB0400781D0 (en) * 2004-01-14 2004-02-18 Novartis Ag Organic compounds
EP1964548A1 (en) * 2007-03-02 2008-09-03 Novartis AG Pharmaceutical compositions comprising a calcilytic agent

Also Published As

Publication number Publication date
CA2644380A1 (en) 2007-10-11
NO20084543L (no) 2008-10-21
RU2008142831A (ru) 2010-05-10
KR20080110769A (ko) 2008-12-19
MA30341B1 (fr) 2009-04-01
PE20071149A1 (es) 2007-12-04
AU2007234021A1 (en) 2007-10-11
ECSP088781A (es) 2008-10-31
US20100227889A1 (en) 2010-09-09
CL2007000850A1 (es) 2008-03-14
WO2007112913A2 (en) 2007-10-11
JP2009531363A (ja) 2009-09-03
BRPI0710180A2 (pt) 2011-08-09
TNSN08369A1 (en) 2009-12-29
IL193475A0 (en) 2009-05-04
TW200806647A (en) 2008-02-01
CN101400669A (zh) 2009-04-01
AU2007234021B2 (en) 2011-04-28
CR10199A (es) 2008-10-16
EP2004629A2 (en) 2008-12-24
WO2007112913A3 (en) 2007-12-21
MX2008012403A (es) 2008-10-07
ZA200806833B (en) 2009-05-27
GT200800200A (es) 2008-11-10
GB0606426D0 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
AR060334A1 (es) Derivados de benzimidazol
ES2491140T3 (es) Derivados de flavona enantioméricamente puros para el tratamiento de trastornos proliferativos y procesos para su preparación
CY1111671T1 (el) Ετεροκυκλικη ενωση
BR112014026457A2 (pt) compostos de tetrazolinona e seu uso como pesticidas
EA200970478A1 (ru) Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
EA201200826A1 (ru) Инсектицидные соединения, основанные на производных изоксазолина
AR096246A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
NZ734896A (en) Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
BR112015006439A2 (pt) compostos de tetrazolinona e seu uso como pesticidas
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
EA200802403A1 (ru) Азолилметилоксираны, их применение для борьбы с фитопатогенными грибами, а также содержащие их средства
PE20090042A1 (es) Analogos de ciclopamina
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
ME01992B (me) Jedinjenje diarilhidantoina
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
MEP8409A (en) Fused heterocyclic compound
AR069702A1 (es) Derivados de 1,2 oxazol como insecticidas
AR069310A1 (es) Inhibidores de beta- lactamasa
RS53292B (en) CRYSTAL FORMS 2-THIAZOLYL-4-HINOLINYL-OXY DERIVATIVES, POWERFUL HCV INHIBITOR
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
EA201170384A1 (ru) Пиррольные соединения
AR049861A1 (es) Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los co0ntienen.
CO6270288A2 (es) Composicion fungicida que comprende cantidades significativamente efectivas de un derivadio de amida de acido carboxilico o su sal
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
EA201070138A1 (ru) Производные плевромутилина и их применение в качестве антимикробных средств

Legal Events

Date Code Title Description
FA Abandonment or withdrawal